SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 ...
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the ...
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis Telesis Bio, a leading provider of DNA and mRNA synthesis ...
Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and ...
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, ...
Telesis Bio and Beckman Coulter Life Sciences announced an new partnership on Thursday. The companies aim to revolutionize DNA and mRNA synthesis by creating efficient and scalable biofoundries.
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the ...
SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced Daniel Gibson, Ph.D., CTO and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback